Exercise-Induced Oxygen Desaturation and Outcomes After Nintedanib Therapy for Fibrosing Interstitial Lung Disease in Patients Without Dyspnea
Authors:
- Masaki OkamotoMOMasaki Okamoto
- Toyoshi YanagiharaTYToyoshi Yanagihara
- Kiminori FujimotoKFKiminori Fujimoto
- Tomonori ChikasueTCTomonori Chikasue
- Kazuhiro TabataKTKazuhiro Tabata
- Yoshiaki ZaizenYZYoshiaki Zaizen
- Masaki TominagaMTMasaki Tominaga
- Akiko SumiASAkiko Sumi
- Yuuya NishiiYNYuuya Nishii
- Norikazu MatsuoNMNorikazu Matsuo
- Takashi NounoTNTakashi Nouno
- Shuji MatsuuraSMShuji Matsuura
Open Access
- 23 December 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (24) , 7865
Abstract
Background: The degree of exercise-induced oxygen desaturation and outcomes following antifibrotic drug therapy in asymptomatic patients with fibrosing interstitial lung disease (FILD) remain unclear. Methods: We compared clinical data, incidence of annual FILD progression, overall survival, and tolerability after initiating nintedanib between 58 patients with dyspnea and 18 patients without. Annual FILD progression was defined as >10% decrease in forced vital capacity (FVC), >15% decrease in diffusing capacity of the lungs for carbon monoxide (DLCO), developing acute exacerbations, or FILD-related death within 1 year of starting nintedanib. Outcomes between the two groups were adjusted for covariates, including age, gender, FVC, DLCO, and diagnosis of idiopathic pulmonary fibrosis, all known prognostic factors for FILD. Results: In 6-min walk test, incidence of decrease to 4% decreases showed no significant difference (71% vs. 89%, p = 0.11) The incidence of annual progression was significantly lower in non-dyspnea than in dyspnea group (17% vs. 53%, adjusted p = 0.026). The relative change in DLCO was significantly slower in non-dyspnea group (adjusted p = 0.036), but FVC was not (adjusted p = 0.067). Overall survival was longer in non-dyspnea group (adjusted p = 0.0089). The discontinuation rate and therapeutic period of nintedanib were not significantly different between the groups. Conclusions: Asymptomatic patients with FILD have severe exercise-induced oxygen desaturation and better outcomes after nintedanib therapy than symptomatic patients. Antifibrotic drug therapy should not be avoided solely because of a lack of symptoms.Keywords
Funding Information
- Department of Respirology at the NHO Kyushu Medical Center
This publication has 39 references indexed in Scilit:
- GOLD COPD report: 2024 updateThe Lancet Respiratory Medicine, 2023
- Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline CharacteristicsAdvances in Therapy, 2023
- A Systematic Review and Meta-analysis of Clinical, Respiratory, and Biochemical Risk Factors for Acute Exacerbation of idiopathic Pulmonary FibrosisArchives of Medical Research, 2023
- Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary FibrosisChest, 2021
- Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosisRespiratory Investigation, 2021
- Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled studyThe Lancet Respiratory Medicine, 2019
- Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosisScientific Reports, 2019
- Japanese guideline for the treatment of idiopathic pulmonary fibrosisRespiratory Investigation, 2018
- Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosisScientific Reports, 2017
- Dyspnoea at 6-min walk test in idiopathic pulmonary fibrosis: Comparison with COPDRespiratory Medicine, 2007